SELENIUM 10 MICROGRAMS/ML SOLUTION FOR INFUSION
NAME OF THE MEDICINAL PRODUCT
SELENIUM 10 micrograms/ml concentrate for solution for infusion
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial of 10 ml solution contains 219 micrograms of sodium selenite, equivalent to
100 micrograms of selenium.
Each ml of solution contains 21.9 micrograms of sodium selenite, equivalent to 10
micrograms of selenium.
For the full list of excipients, see section 6.1.
Concentrate for solution for infusion.
Clear colourless solution.
pH 8.0 – 9.5
Osmolarity = 20 mOsm/l
Prevention of selenium deficiency in patients receiving parenteral nutrition.
Treatment of proven selenium deficiency that cannot be compensated by nutrition
Posology and method of administration
1 ml of solution contains 10 micrograms of selenium.
The dose must be adapted individually according to selenium deficiency and selenium
For monitoring of therapy the selenium concentration in whole blood or serum should
In long term parenteral nutrition, control of blood levels should be performed at 6-12
months intervals, except if clinical symptoms of a deficiency are suspected.
Plasma selenium concentrations from 80 to 120 µ/L (in whole blood: 100 to140 µg/l)
have been proposed to be adequate in adults. At levels above the normal selenium
levels, the dose should be reduced.
Age specific reference values for normal selenium concentrations apply for
monitoring of therapy.
The recommended posology is:
o Supplementation to total parenteral nutrition: 60 to 100 micrograms daily.
o Other situation with proven selenium deficiency: 100 micrograms up to a
maximum of 400 micrograms daily for a short-term until normalization of
laboratory monitoring values.
o Infants: 2 micrograms/kg/day and infants with low birth weight: 2 to 3
o Children: 2 micrograms/kg/day, up to a maximum of 30 micrograms daily.
Method of administration
SELENIUM 10 micrograms/ml concentrate for solution for infusion must be
administered after dilution in solution for parenteral nutrition, after stability has been
validated, or in isotonic solution (such as sodium chloride 0.9% or glucose 5%) with a
slow infusion rate.
This product must not be administrated in case of selenium poisoning or
hypersensitivity to selenium containing products.
Special warnings and precautions for use
The product must not be injected straight, but diluted in a solution for infusion (see
Precautions for use:
Serum selenium levels must be controlled regularly.
In case of complex parenteral nutrition and if mixing of medicines is necessary,
caution is required in order to avoid incompatibilities.
Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
Fertility, pregnancy and lactation
There are no data from the use of Selenium in pregnant women. Limited published
data from animal studies reveal only evidence for toxicity to reproduction at
maternally toxic doses (see section 5.3.). No adverse effect of sodium selenite on the
pregnancy or unborn child is expected, provided that it is used in case of proven
Selenium is excreted in human milk, but at therapeutic doses of selenium no effects
on the breastfed newborns/infants are anticipated. Selenium can be used during
There are no data on fertility from the use of selenium in humans. Selenium did not
impair male fertility in rats, and effects of selenium on female fertility in rodents were
only observed at very high doses (see section 5.3). Overall, doses used to correct
selenium deficiency are not expected to exert adverse effects on fertility.
Effects on ability to drive and use machines
SELENIUM 10 micrograms/ml concentrate for solution for infusion has no influence
on the ability to drive and use machines.
No adverse effects are observed in normal conditions of use.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse reactions
via the national reporting system listed in Appendix V.
Symptoms of acute overdose are: garlicky breath, tiredness, nausea and vomiting,
diarrhoea and abdominal pain. In case of chronic overdose, effects on skin and skin
appendages with changes in the nail and hair growth as well as peripheral
polyneuropathies have been observed.
In case of overdose, the treatment must be interrupted, and a symptomatic treatment
should be given if necessary. In case of acute overdose by ingestion of large amount
of selenium, gastric lavage and forced diuresis are possible. In case of extreme
overdose (1,000 – 10,000x), elimination of selenite by dialysis can be attempted.
There is no known specific antidote.
In case of intoxication, selenium blood levels should be controlled at least once a
month, until return to a level conform to the recommendations.
Pharmacotherapeutic group: Mineral supplements.
ATC code: A12CE02
Selenium is an essential trace element. Up to 20 selenoproteins have been identified
in rodents. In human, selenium compounds are glutathione peroxidase and a selenium
protein P found in the plasma. In both these proteins, selenium is protein-bound and is
present in the form of the amino acid selenocysteine. Other selenium-dependent
enzymes are the thioredoxine-reductase and the 5'-deiodinase that catalyses the
conversion from tetraiodothyronine (T4) to the active thyroid hormone
The selenium-containing glutathionperoxidase is a part of the anti-oxidative
protection system of the mammal cell. In case of sufficient quantities of reduced
glutathione, the glutathionperoxidase converts a variety of hydroperoxides into
relevant alcohols. In cellular or sub-cellular in vitro models, it has been observed that
the integrity of cellular or sub-cellular membranes depends on the intactness of the
glutathionperoxidase system. Synergetic effect with vitamin E in various cell
fractions is postulated but has not been conclusively proven. Selenium as a part of the
glutathionperoxidase can reduce the lipidperoxide rate and the resulting membrane
The patho-physiological relevance of selenium-dependent reactions has been
demonstrated by observations in selenium deficiency humans and animals. The
selenium-containing glutathionperoxidase affects the leucotriene, thromboxane and
prostacyclin metabolism. Selenium deficiency inhibits reactions of the immune
system, especially the non-specific, cell-bound and humoral reactions. Selenium
deficiency affects the activity of a few liver enzymes. Selenium deficiency potentiates
oxidatively or chemically induced liver damage and toxicity of heavy metals such as
quicksilver and cadmium.
Deficiency of selenium has been associated with an endemic form of
cardiomyopathy, Keshan disease. It has also been associated with Kaschin-Beck
disease, an endemic osteoarthropathy which causes a severe deformity of the joints.
Clinically manifested selenium deficiency has also been seen to be a result of longterm parenteral nutrition and unbalanced diets. Cardiomyopathies and myopathies are
observed most frequently.
In the blood, selenite is mainly absorbed by erythrocytes and enzymatically reduced
to hydrogen selenide. Hydrogen selenide serves as the central selenium pool for
excretion and for specific incorporation in selenoproteins. In this reduced form,
selenium is bound to plasma proteins present in the liver and other organs. The
plasmatic secondary transport from the liver to the glutathionperoxidase-synthesing
target tissues takes place in the form of selenocystein (selenoprotein P). The further
metabolic process of the selenoprotein biosynthesis is currently known only in
prokaryotes. Selenocystein is then specifically incorporated into the peptide chains of
Excess of hydrogen selenide is transformed into methylated metabolites (methyl
selenol, dimethylselenide and trimethylselenonium ion) prior to being excreted into
urine and/or exhaled.
The total quantity of selenium in the human body is between 3 mg and 20 mg. In
human, selenium is excreted in feces, urine or lung, depending on the administered
dosage. Selenium is primarily renally excreted in the form of trimethylselenonium
ion. The excretion depends on the selenium status.
The selenium excretion after the intravenous or oral intake takes place in three phases
with a terminal half-life of 65 to 116 days.
Preclinical safety data
Published literature on single and repeated dose toxicity of selenium and sodium
selenite reveals no evidence for adverse health effects in addition to those already
known from experience in humans. Toxicity to reproduction was only found at very
high doses and no evidence was found for a risk of teratogenic effects in mammals at
non-maternally toxic doses. Although mutagenicity and carcinogenicity data are
inconclusive, because there is evidence for both positive as well as negative effects,
the adverse effects on these endpoints are generally found at concentrations above the
normal physiological levels.
List of excipients
Water for injection.
Selenium is generally incompatible with high concentration of ascorbic acid
(reduction of selenite to elemental selenium which is not soluble and unavailable as a
nutritional source of selenium).
SELENIUM 10 micrograms/ml concentrate for solution for infusion can not be mixed
with medicines except those mentionned in section 6.6.
After dilution, chemical and physical in-use stability has been demonstrated for 48 h
From a microbiological point of view, the product should be used immediately. If not
used immediately, in-use storage times and conditions prior to use are the
responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C,
unless dilution has taken place in controlled and validated aseptic conditions.
Special precautions for storage
There are no special storage conditions.
Nature and contents of container
10 ml solution in a type I glass vial with a type I elastomer (bromobutyl) stopper
fitted with an aluminium cover and crimped.
Pack of 10 vials.
Special precautions for disposal
SELENIUM 10 micrograms/ml concentrate for solution for infusion can not be mixed
with medicines other than sodium chloride 0.9%, glucose 5%, solution for parenteral
nutrition or solution of trace elements.
Each ml of concentrate should be diluted in at least 5 ml of solution for infusion.
Any unused medicinal product or waste material should be disposed of in accordance
with local requirements.
MARKETING AUTHORISATION HOLDER
1, rue Alexander Fleming
MARKETING AUTHORISATION NUMBER(S)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
DATE OF REVISION OF THE TEXT